Table of Contents Author Guidelines Submit a Manuscript
Journal of Pharmaceutics
Volume 2014, Article ID 713650, 7 pages
http://dx.doi.org/10.1155/2014/713650
Research Article

The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients

1Department of Pharmacy, Tianjin First Central Hospital, Tianjin 300192, China
2Basic Medical College, Tianjin Medical University, Tianjin 300070, China
3Department of Liver Transplantation, Tianjin First Central Hospital, Tianjin 300192, China
4Department of Liver Transplantation, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Received 18 November 2013; Revised 7 January 2014; Accepted 8 January 2014; Published 13 February 2014

Academic Editor: Pradeep Tyagi

Copyright © 2014 Liqin Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. E. Staatz and S. E. Tett, “Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation,” Clinical Pharmacokinetics, vol. 43, no. 10, pp. 623–653, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. J. E. Wallin, L. E. Friberg, A. Fasth, and C. E. Staatz, “Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool,” Therapeutic Drug Monitoring, vol. 31, no. 4, pp. 457–466, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. F. T. Musuamba, M. Mourad, V. Haufroid, I. K. Delattre, R. K. Verbeeck, and P. Wallemacq, “Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study,” Therapeutic Drug Monitoring, vol. 31, no. 6, pp. 734–742, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. B. S. Mathew, D. H. Fleming, V. Jeyaseelan et al., “A limited sampling strategy for tacrolimus in renal transplant patients,” British Journal of Clinical Pharmacology, vol. 66, no. 4, pp. 467–472, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Miura, S. Satoh, T. Niioka et al., “Early phase limited sampling strategy characterizing tacrolimus and mycophenolic acid pharmacokinetics adapted to the maintenance phase of renal transplant patients,” Therapeutic Drug Monitoring, vol. 31, no. 4, pp. 467–474, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Antignac, J. S. Hulot, E. Boleslawski et al., “Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance,” European Journal of Clinical Pharmacology, vol. 61, no. 5-6, pp. 409–416, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Fukatsu, I. Yano, T. Igarashi et al., “Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation,” European Journal of Clinical Pharmacology, vol. 57, no. 5-6, pp. 479–484, 2001. View at Google Scholar · View at Scopus
  8. M. Macchi-Andanson, B. Charpiat, R. W. Jelliffe, C. Ducerf, N. Fourcade, and J. Baulieux, “Failure of traditional trough levels to predict tacrolimus concentrations,” Therapeutic Drug Monitoring, vol. 23, no. 2, pp. 129–133, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. J. S. Wai, S. T. Lai, M. J. Holmes et al., “Population pharmacokinetics of tacrolimus in whole blood and plasma in Asian liver transplant patients,” Clinical Pharmacokinetics, vol. 45, no. 1, pp. 59–75, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. C. E. Staatz, C. Willis, P. J. Taylor, S. V. Lynch, and S. E. Tett, “Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation,” Liver Transplantation, vol. 9, no. 2, pp. 130–137, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Fukudo, I. Yano, S. Masuda et al., “Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients,” Clinical Pharmacology and Therapeutics, vol. 80, no. 4, pp. 331–345, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. M. J. Garcia Sanchez, C. Manzanares, D. Santos-Buelga et al., “Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy,” Clinical Pharmacokinetics, vol. 40, no. 1, pp. 63–71, 2001. View at Google Scholar · View at Scopus
  13. C. E. Staatz, P. J. Taylor, S. V. Lynch, C. Willis, B. G. Charles, and S. E. Tett, “Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants,” Transplantation, vol. 72, no. 6, pp. 1056–1061, 2001. View at Google Scholar · View at Scopus
  14. J. E. Wallin, M. Bergstrand, H. Wilczek, P. S. Nydert, M. O. Karlsson, and C. E. Staatz, “Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance,” Therapeutic Drug Monitoring, vol. 33, no. 6, pp. 663–672, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Brendel, C. Dartois, E. Comets et al., “Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004,” Clinical Pharmacokinetics, vol. 46, no. 3, pp. 221–234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Jolling, J. J. Perez Ruixo, A. Hemeryck, A. Vermeulen, and T. Greway, “Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin,” European Journal of Pharmaceutical Sciences, vol. 24, no. 5, pp. 465–475, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. T. M. Post, J. I. Freijer, B. A. Ploeger, and M. Danhof, “Extensions to the Visual Predictive Check to facilitate model performance evaluation,” Journal of Pharmacokinetics and Pharmacodynamics, vol. 35, no. 2, pp. 185–202, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Antignac, J. S. Hulot, E. Boleslawski et al., “Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance,” European Journal of Clinical Pharmacology, vol. 61, no. 5-6, pp. 409–416, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. C. E. Staatz, C. Willis, P. J. Taylor, S. V. Lynch, and S. E. Tett, “Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation,” Liver Transplantation, vol. 9, no. 2, pp. 130–137, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. F. T. Aweeka, L. Z. Benet, J. G. Gambertoglio et al., “Comparative pharmacokinetics of orally (PO) and intravenously (IV) administered tacrolimus (FK506) in pre- and post-kidney transplant recipients,” Clinical Pharmacology & Therapeutics, vol. 53, no. 2, p. 151, 1993. View at Google Scholar
  21. N. A. Undre and A. Schäfer, “Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation,” Transplantation Proceedings, vol. 30, no. 4, pp. 1261–1263, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. R. R. Press, B. A. Ploeger, J. D. Hartigh et al., “Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients,” Therapeutic Drug Monitoring, vol. 31, no. 2, pp. 187–197, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. C. E. Staatz, L. K. Goodman, and S. E. Tett, “Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I,” Clinical Pharmacokinetics, vol. 49, no. 3, pp. 141–175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Marzolini, E. Paus, T. Buclin, and R. B. Kim, “Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance,” Clinical Pharmacology and Therapeutics, vol. 75, no. 1, pp. 13–33, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. X.-J. Shi, F. Geng, Z. Jiao, X.-Y. Cui, X.-Y. Qiu, and M.-K. Zhong, “Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis,” Journal of Clinical Pharmacy and Therapeutics, vol. 36, no. 5, pp. 614–624, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Zahir, A. J. McLachlan, A. Nelson, G. McCaughan, M. Gleeson, and F. Akhlaghi, “Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients,” Therapeutic Drug Monitoring, vol. 27, no. 4, pp. 422–430, 2005. View at Publisher · View at Google Scholar · View at Scopus